292 related articles for article (PubMed ID: 9130039)
1. Sibutramine--a review of clinical efficacy.
Lean ME
Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
3. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
5. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
[TBL] [Abstract][Full Text] [Related]
6. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
7. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
Hung YJ; Chen YC; Pei D; Kuo SW; Hsieh CH; Wu LY; He CT; Lee CH; Fan SC; Sheu WH
Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
[TBL] [Abstract][Full Text] [Related]
8. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
Cuellar GE; Ruiz AM; Monsalve MC; Berber A
Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
[TBL] [Abstract][Full Text] [Related]
9. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
Van Gaal LF; Wauters MA; De Leeuw IH
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
[TBL] [Abstract][Full Text] [Related]
10. Sibutramine produces dose-related weight loss.
Bray GA; Blackburn GL; Ferguson JM; Greenway FL; Jain AK; Mendel CM; Mendels J; Ryan DH; Schwartz SL; Scheinbaum ML; Seaton TB
Obes Res; 1999 Mar; 7(2):189-98. PubMed ID: 10102256
[TBL] [Abstract][Full Text] [Related]
11. The discovery and status of sibutramine as an anti-obesity drug.
Luque CA; Rey JA
Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
[TBL] [Abstract][Full Text] [Related]
12. A benefit-risk assessment of sibutramine in the management of obesity.
Nisoli E; Carruba MO
Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
[TBL] [Abstract][Full Text] [Related]
13. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
14. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
15. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
16. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
17. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
[TBL] [Abstract][Full Text] [Related]
18. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
Finer N; Ryan DH; Renz CL; Hewkin AC
Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
[TBL] [Abstract][Full Text] [Related]
20. Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
Stock MJ
Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S25-9. PubMed ID: 9130038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
